Evidence map›Paper›PMID 30128433›Full record

ArticleHematology, transfusion and cell therapy

Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group.

Juliano Júlio Cerci, Mateos Bogoni, Valeria Buccheri, Elba Cristina Sá de Camargo Etchebehere, Talita Maira Bueno da Silveira, Otavio Baiocchi, Carlos de Araujo Cunha Pereira Neto, Marcelo Tatit Sapienza, Jose Flavio Gomes Marin, José Cláudio Meneghetti and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Hematology, transfusion and cell therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Juliano Júlio CerciQuanta Diagnóstico e Terapia, Curitiba, PR, Brazil. Electronic address: cercijuliano@hotmail.com.
Mateos BogoniQuanta Diagnóstico e Terapia, Curitiba, PR, Brazil.
Valeria BuccheriUniversidade de São Paulo (USP), Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil.
Elba Cristina Sá de Camargo EtchebehereHospital Sírio Libanês, São Paulo, SP, Brazil.
Talita Maira Bueno da SilveiraHospital Samaritano, São Paulo, SP, Brazil.
Otavio BaiocchiUniversidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil.
Carlos de Araujo Cunha Pereira NetoQuanta Diagnóstico e Terapia, Curitiba, PR, Brazil.
Marcelo Tatit SapienzaUniversidade de São Paulo (USP), Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil.
Jose Flavio Gomes MarinHospital Samaritano, São Paulo, SP, Brazil.
José Cláudio MeneghettiUniversidade de São Paulo (USP), Hospital das Clínicas (HC), Instituto do Coração (InCor), São Paulo, SP, Brazil.
Yana NovisHospital Sírio Libanês, São Paulo, SP, Brazil.
Carmino Antonio de SouzaUniversidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil.
Carlos ChiattoneHospital Samaritano, São Paulo, SP, Brazil.
Marcia TorresanUniversidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil.
Celso Dario RamosUniversidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil.
Hospital Samaritano de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BRHospital Sírio-Libanês · BRHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRInstituto do Câncer do Estado de São Paulo · BRUniversidade de São Paulo · BRUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate, in a large prospective multicenter study, whether 2-[18F]-fluoro-2-deoxy-d-glucose-positron emission tomography is sufficiently accurate to identify clinically important bone marrow involvement by Hodgkin's lymphoma to replace routine bone marrow biopsy in a developing tropical country.

methodsPatients newly diagnosed with Hodgkin's lymphoma were recruited from six cancer centers in Brazil. All were staged by the results of positron emission tomography/computed tomography that were centrally reviewed and by iliac crest bone marrow biopsy. Patients were classified as having marrow disease if they had lymphoma identified by marrow biopsy histology or had focal 2-[18F]-fluoro-2-deoxy-d-glucose marrow uptake that resolved following chemotherapy.

resultsA total of 246 participants were recruited from six different centers and 62 (25.2%) were judged to have Hodgkin's lymphoma in the bone marrow. Positron emission tomography and biopsies were concordant in 206 patients (83%). Positron emission tomography correctly identified marrow disease in 59/62 patients (95.1%) and marrow biopsy in 25/62 patients (40.3%). In 22/62 (35.4%) patients, the two techniques were concordant in the diagnosis of marrow involvement. Of the forty discordant results, positron emission tomography found bone marrow involvement in 37 patients, upstaging 22 to stage IV and having an impact on therapeutic decision in nine cases given their reallocation from early to advanced stage. Three false negative positron emission tomography results were obtained with bone marrow biopsy giving positive findings. All three cases were classified as stage IV regardless of bone marrow findings implying no modification in the clinical management. The sensitivity, specificity and accuracy of positron emission tomography for detecting bone marrow disease were 95%, 100% and 98% and for bone marrow biopsy they were 40%, 100% and 84%, respectively.

conclusionWe conclude that positron emission tomography can replace marrow biopsy in Brazilian patients with Hodgkin's lymphoma without compromising clinical management.

Indexed as

Bone marrow biopsyFDG-PETHodgkin's lymphomaLymphoma stagingPositron-emission tomography

Identifiers

PMID30128433
PMCPMC6098181
OpenAlexW2799980813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.